Intel has announced that three members of its 14-person board of directors will not seek reelection at the 2025 annual meeting on May 5, reducing the board to 11. This shift is significant as two of the departing directors come from the healthcare industry, indicating a move towards a more high-tech industry-focused board.

The departing directors are Dr. Omar Ishrak, former chair of Intel; Dr. Risa Lavizzo-Mourey, a former University of Pennsylvania professor; and Dr. Tsu-Jae King Liu, a UC Berkeley engineering dean. Their exits follow the recent additions of Eric Meurice, ex-CEO of ASML, and Steve Sanghi, interim chief of Microchip Technology.

This adjustment continues Intel's move away from its previous board composition, which included directors from academia, finance, healthcare, and the PC industry. The new board will have a stronger emphasis on industry-specific knowledge, which could be crucial in supporting Intel's efforts to regain its competitive edge in products and process technology.

Frank D. Yeary, Intel's chairman with a background in finance, wrote to shareholders, emphasizing the commitment to having the right mix of skills, qualifications, and technical expertise on the board. The inclusion of Eric Meurice and Steve Sanghi as independent directors is seen as a positive step towards this goal.